Global Neuroendocrine Carcinoma Market Research Report 2023

Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous systems. Many are benign, while some are malignant. They most commonly occur in the intestine, where they are often called carcinoid tumors, but they are also found in the pancreas, lung and the rest of the body.

The global Neuroendocrine Carcinoma market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

The somatostatin analogs segment by treatment type is expected to witness high traction in the coming years.

This report aims to provide a comprehensive presentation of the global market for Neuroendocrine Carcinoma, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuroendocrine Carcinoma.

The Neuroendocrine Carcinoma market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Neuroendocrine Carcinoma market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Neuroendocrine Carcinoma companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Neuroendocrine Carcinoma Market Size Growth Rate by Type: 2018 VS 2022 VS 2029

1.2.2 Chemotherapy

1.2.3 Somatostatin Analogs

1.2.4 Targeted Therapy

1.3 Market by Application

1.3.1 Global Neuroendocrine Carcinoma Market Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Hospital

1.3.3 Clinics

1.3.4 Oncology Centres

1.3.5 Ambulatory Surgery Centres

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2.1 Global Neuroendocrine Carcinoma Market Perspective (2018-2029)

2.2 Neuroendocrine Carcinoma Growth Trends by Region

2.2.1 Global Neuroendocrine Carcinoma Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Neuroendocrine Carcinoma Historic Market Size by Region (2018-2023)

2.2.3 Neuroendocrine Carcinoma Forecasted Market Size by Region (2024-2029)

2.3 Neuroendocrine Carcinoma Market Dynamics

2.3.1 Neuroendocrine Carcinoma Industry Trends

2.3.2 Neuroendocrine Carcinoma Market Drivers

2.3.3 Neuroendocrine Carcinoma Market Challenges

2.3.4 Neuroendocrine Carcinoma Market Restraints

3.1 Global Top Neuroendocrine Carcinoma Players by Revenue

3.1.1 Global Top Neuroendocrine Carcinoma Players by Revenue (2018-2023)

3.1.2 Global Neuroendocrine Carcinoma Revenue Market Share by Players (2018-2023)

3.2 Global Neuroendocrine Carcinoma Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Neuroendocrine Carcinoma Revenue

3.4 Global Neuroendocrine Carcinoma Market Concentration Ratio

3.4.1 Global Neuroendocrine Carcinoma Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Neuroendocrine Carcinoma Revenue in 2022

3.5 Neuroendocrine Carcinoma Key Players Head office and Area Served

3.6 Key Players Neuroendocrine Carcinoma Product Solution and Service

3.7 Date of Enter into Neuroendocrine Carcinoma Market

3.8 Mergers & Acquisitions, Expansion Plans

4.1 Global Neuroendocrine Carcinoma Historic Market Size by Type (2018-2023)

4.2 Global Neuroendocrine Carcinoma Forecasted Market Size by Type (2024-2029)

5.1 Global Neuroendocrine Carcinoma Historic Market Size by Application (2018-2023)

5.2 Global Neuroendocrine Carcinoma Forecasted Market Size by Application (2024-2029)

6.1 North America Neuroendocrine Carcinoma Market Size (2018-2029)

6.2 North America Neuroendocrine Carcinoma Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Neuroendocrine Carcinoma Market Size by Country (2018-2023)

6.4 North America Neuroendocrine Carcinoma Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7.1 Europe Neuroendocrine Carcinoma Market Size (2018-2029)

7.2 Europe Neuroendocrine Carcinoma Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Neuroendocrine Carcinoma Market Size by Country (2018-2023)

7.4 Europe Neuroendocrine Carcinoma Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8.1 Asia-Pacific Neuroendocrine Carcinoma Market Size (2018-2029)

8.2 Asia-Pacific Neuroendocrine Carcinoma Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Neuroendocrine Carcinoma Market Size by Region (2018-2023)

8.4 Asia-Pacific Neuroendocrine Carcinoma Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9.1 Latin America Neuroendocrine Carcinoma Market Size (2018-2029)

9.2 Latin America Neuroendocrine Carcinoma Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Neuroendocrine Carcinoma Market Size by Country (2018-2023)

9.4 Latin America Neuroendocrine Carcinoma Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

10.1 Middle East & Africa Neuroendocrine Carcinoma Market Size (2018-2029)

10.2 Middle East & Africa Neuroendocrine Carcinoma Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Neuroendocrine Carcinoma Market Size by Country (2018-2023)

10.4 Middle East & Africa Neuroendocrine Carcinoma Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11.1 Pfizer

11.1.1 Pfizer Company Detail

11.1.2 Pfizer Business Overview

11.1.3 Pfizer Neuroendocrine Carcinoma Introduction

11.1.4 Pfizer Revenue in Neuroendocrine Carcinoma Business (2018-2023)

11.1.5 Pfizer Recent Development

11.2 Novartis

11.2.1 Novartis Company Detail

11.2.2 Novartis Business Overview

11.2.3 Novartis Neuroendocrine Carcinoma Introduction

11.2.4 Novartis Revenue in Neuroendocrine Carcinoma Business (2018-2023)

11.2.5 Novartis Recent Development

11.3 Chiasma

11.3.1 Chiasma Company Detail

11.3.2 Chiasma Business Overview

11.3.3 Chiasma Neuroendocrine Carcinoma Introduction

11.3.4 Chiasma Revenue in Neuroendocrine Carcinoma Business (2018-2023)

11.3.5 Chiasma Recent Development

11.4 Ipsen

11.4.1 Ipsen Company Detail

11.4.2 Ipsen Business Overview

11.4.3 Ipsen Neuroendocrine Carcinoma Introduction

11.4.4 Ipsen Revenue in Neuroendocrine Carcinoma Business (2018-2023)

11.4.5 Ipsen Recent Development

11.5 Abbvie

11.5.1 Abbvie Company Detail

11.5.2 Abbvie Business Overview

11.5.3 Abbvie Neuroendocrine Carcinoma Introduction

11.5.4 Abbvie Revenue in Neuroendocrine Carcinoma Business (2018-2023)

11.5.5 Abbvie Recent Development

11.6 Valeant

11.6.1 Valeant Company Detail

11.6.2 Valeant Business Overview

11.6.3 Valeant Neuroendocrine Carcinoma Introduction

11.6.4 Valeant Revenue in Neuroendocrine Carcinoma Business (2018-2023)

11.6.5 Valeant Recent Development

11.7 Jubilant

11.7.1 Jubilant Company Detail

11.7.2 Jubilant Business Overview

11.7.3 Jubilant Neuroendocrine Carcinoma Introduction

11.7.4 Jubilant Revenue in Neuroendocrine Carcinoma Business (2018-2023)

11.7.5 Jubilant Recent Development

11.8 Teva

11.8.1 Teva Company Detail

11.8.2 Teva Business Overview

11.8.3 Teva Neuroendocrine Carcinoma Introduction

11.8.4 Teva Revenue in Neuroendocrine Carcinoma Business (2018-2023)

11.8.5 Teva Recent Development

11.9 F.Hoffmann-La Roche

11.9.1 F.Hoffmann-La Roche Company Detail

11.9.2 F.Hoffmann-La Roche Business Overview

11.9.3 F.Hoffmann-La Roche Neuroendocrine Carcinoma Introduction

11.9.4 F.Hoffmann-La Roche Revenue in Neuroendocrine Carcinoma Business (2018-2023)

11.9.5 F.Hoffmann-La Roche Recent Development

11.10 Advanced Accelerator

11.10.1 Advanced Accelerator Company Detail

11.10.2 Advanced Accelerator Business Overview

11.10.3 Advanced Accelerator Neuroendocrine Carcinoma Introduction

11.10.4 Advanced Accelerator Revenue in Neuroendocrine Carcinoma Business (2018-2023)

11.10.5 Advanced Accelerator Recent Development

11.11 Mateon

11.11.1 Mateon Company Detail

11.11.2 Mateon Business Overview

11.11.3 Mateon Neuroendocrine Carcinoma Introduction

11.11.4 Mateon Revenue in Neuroendocrine Carcinoma Business (2018-2023)

11.11.5 Mateon Recent Development

11.12 Lexicon

11.12.1 Lexicon Company Detail

11.12.2 Lexicon Business Overview

11.12.3 Lexicon Neuroendocrine Carcinoma Introduction

11.12.4 Lexicon Revenue in Neuroendocrine Carcinoma Business (2018-2023)

11.12.5 Lexicon Recent Development

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

    Table 1. Global Neuroendocrine Carcinoma Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029

    Table 2. Key Players of Chemotherapy

    Table 3. Key Players of Somatostatin Analogs

    Table 4. Key Players of Targeted Therapy

    Table 5. Global Neuroendocrine Carcinoma Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029

    Table 6. Global Neuroendocrine Carcinoma Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 7. Global Neuroendocrine Carcinoma Market Size by Region (2018-2023) & (US$ Million)

    Table 8. Global Neuroendocrine Carcinoma Market Share by Region (2018-2023)

    Table 9. Global Neuroendocrine Carcinoma Forecasted Market Size by Region (2024-2029) & (US$ Million)

    Table 10. Global Neuroendocrine Carcinoma Market Share by Region (2024-2029)

    Table 11. Neuroendocrine Carcinoma Market Trends

    Table 12. Neuroendocrine Carcinoma Market Drivers

    Table 13. Neuroendocrine Carcinoma Market Challenges

    Table 14. Neuroendocrine Carcinoma Market Restraints

    Table 15. Global Neuroendocrine Carcinoma Revenue by Players (2018-2023) & (US$ Million)

    Table 16. Global Neuroendocrine Carcinoma Market Share by Players (2018-2023)

    Table 17. Global Top Neuroendocrine Carcinoma Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuroendocrine Carcinoma as of 2022)

    Table 18. Ranking of Global Top Neuroendocrine Carcinoma Companies by Revenue (US$ Million) in 2022

    Table 19. Global 5 Largest Players Market Share by Neuroendocrine Carcinoma Revenue (CR5 and HHI) & (2018-2023)

    Table 20. Key Players Headquarters and Area Served

    Table 21. Key Players Neuroendocrine Carcinoma Product Solution and Service

    Table 22. Date of Enter into Neuroendocrine Carcinoma Market

    Table 23. Mergers & Acquisitions, Expansion Plans

    Table 24. Global Neuroendocrine Carcinoma Market Size by Type (2018-2023) & (US$ Million)

    Table 25. Global Neuroendocrine Carcinoma Revenue Market Share by Type (2018-2023)

    Table 26. Global Neuroendocrine Carcinoma Forecasted Market Size by Type (2024-2029) & (US$ Million)

    Table 27. Global Neuroendocrine Carcinoma Revenue Market Share by Type (2024-2029)

    Table 28. Global Neuroendocrine Carcinoma Market Size by Application (2018-2023) & (US$ Million)

    Table 29. Global Neuroendocrine Carcinoma Revenue Market Share by Application (2018-2023)

    Table 30. Global Neuroendocrine Carcinoma Forecasted Market Size by Application (2024-2029) & (US$ Million)

    Table 31. Global Neuroendocrine Carcinoma Revenue Market Share by Application (2024-2029)

    Table 32. North America Neuroendocrine Carcinoma Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 33. North America Neuroendocrine Carcinoma Market Size by Country (2018-2023) & (US$ Million)

    Table 34. North America Neuroendocrine Carcinoma Market Size by Country (2024-2029) & (US$ Million)

    Table 35. Europe Neuroendocrine Carcinoma Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 36. Europe Neuroendocrine Carcinoma Market Size by Country (2018-2023) & (US$ Million)

    Table 37. Europe Neuroendocrine Carcinoma Market Size by Country (2024-2029) & (US$ Million)

    Table 38. Asia-Pacific Neuroendocrine Carcinoma Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 39. Asia-Pacific Neuroendocrine Carcinoma Market Size by Region (2018-2023) & (US$ Million)

    Table 40. Asia-Pacific Neuroendocrine Carcinoma Market Size by Region (2024-2029) & (US$ Million)

    Table 41. Latin America Neuroendocrine Carcinoma Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 42. Latin America Neuroendocrine Carcinoma Market Size by Country (2018-2023) & (US$ Million)

    Table 43. Latin America Neuroendocrine Carcinoma Market Size by Country (2024-2029) & (US$ Million)

    Table 44. Middle East & Africa Neuroendocrine Carcinoma Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 45. Middle East & Africa Neuroendocrine Carcinoma Market Size by Country (2018-2023) & (US$ Million)

    Table 46. Middle East & Africa Neuroendocrine Carcinoma Market Size by Country (2024-2029) & (US$ Million)

    Table 47. Pfizer Company Detail

    Table 48. Pfizer Business Overview

    Table 49. Pfizer Neuroendocrine Carcinoma Product

    Table 50. Pfizer Revenue in Neuroendocrine Carcinoma Business (2018-2023) & (US$ Million)

    Table 51. Pfizer Recent Development

    Table 52. Novartis Company Detail

    Table 53. Novartis Business Overview

    Table 54. Novartis Neuroendocrine Carcinoma Product

    Table 55. Novartis Revenue in Neuroendocrine Carcinoma Business (2018-2023) & (US$ Million)

    Table 56. Novartis Recent Development

    Table 57. Chiasma Company Detail

    Table 58. Chiasma Business Overview

    Table 59. Chiasma Neuroendocrine Carcinoma Product

    Table 60. Chiasma Revenue in Neuroendocrine Carcinoma Business (2018-2023) & (US$ Million)

    Table 61. Chiasma Recent Development

    Table 62. Ipsen Company Detail

    Table 63. Ipsen Business Overview

    Table 64. Ipsen Neuroendocrine Carcinoma Product

    Table 65. Ipsen Revenue in Neuroendocrine Carcinoma Business (2018-2023) & (US$ Million)

    Table 66. Ipsen Recent Development

    Table 67. Abbvie Company Detail

    Table 68. Abbvie Business Overview

    Table 69. Abbvie Neuroendocrine Carcinoma Product

    Table 70. Abbvie Revenue in Neuroendocrine Carcinoma Business (2018-2023) & (US$ Million)

    Table 71. Abbvie Recent Development

    Table 72. Valeant Company Detail

    Table 73. Valeant Business Overview

    Table 74. Valeant Neuroendocrine Carcinoma Product

    Table 75. Valeant Revenue in Neuroendocrine Carcinoma Business (2018-2023) & (US$ Million)

    Table 76. Valeant Recent Development

    Table 77. Jubilant Company Detail

    Table 78. Jubilant Business Overview

    Table 79. Jubilant Neuroendocrine Carcinoma Product

    Table 80. Jubilant Revenue in Neuroendocrine Carcinoma Business (2018-2023) & (US$ Million)

    Table 81. Jubilant Recent Development

    Table 82. Teva Company Detail

    Table 83. Teva Business Overview

    Table 84. Teva Neuroendocrine Carcinoma Product

    Table 85. Teva Revenue in Neuroendocrine Carcinoma Business (2018-2023) & (US$ Million)

    Table 86. Teva Recent Development

    Table 87. F.Hoffmann-La Roche Company Detail

    Table 88. F.Hoffmann-La Roche Business Overview

    Table 89. F.Hoffmann-La Roche Neuroendocrine Carcinoma Product

    Table 90. F.Hoffmann-La Roche Revenue in Neuroendocrine Carcinoma Business (2018-2023) & (US$ Million)

    Table 91. F.Hoffmann-La Roche Recent Development

    Table 92. Advanced Accelerator Company Detail

    Table 93. Advanced Accelerator Business Overview

    Table 94. Advanced Accelerator Neuroendocrine Carcinoma Product

    Table 95. Advanced Accelerator Revenue in Neuroendocrine Carcinoma Business (2018-2023) & (US$ Million)

    Table 96. Advanced Accelerator Recent Development

    Table 97. Mateon Company Detail

    Table 98. Mateon Business Overview

    Table 99. Mateon Neuroendocrine Carcinoma Product

    Table 100. Mateon Revenue in Neuroendocrine Carcinoma Business (2018-2023) & (US$ Million)

    Table 101. Mateon Recent Development

    Table 102. Lexicon Company Detail

    Table 103. Lexicon Business Overview

    Table 104. Lexicon Neuroendocrine Carcinoma Product

    Table 105. Lexicon Revenue in Neuroendocrine Carcinoma Business (2018-2023) & (US$ Million)

    Table 106. Lexicon Recent Development

    Table 107. Research Programs/Design for This Report

    Table 108. Key Data Information from Secondary Sources

    Table 109. Key Data Information from Primary Sources

List of Figures

    Figure 1. Global Neuroendocrine Carcinoma Market Size Comparison by Type (2023-2029) & (US$ Million)

    Figure 2. Global Neuroendocrine Carcinoma Market Share by Type: 2022 VS 2029

    Figure 3. Chemotherapy Features

    Figure 4. Somatostatin Analogs Features

    Figure 5. Targeted Therapy Features

    Figure 6. Global Neuroendocrine Carcinoma Market Size Comparison by Application (2023-2029) & (US$ Million)

    Figure 7. Global Neuroendocrine Carcinoma Market Share by Application: 2022 VS 2029

    Figure 8. Hospital Case Studies

    Figure 9. Clinics Case Studies

    Figure 10. Oncology Centres Case Studies

    Figure 11. Ambulatory Surgery Centres Case Studies

    Figure 12. Neuroendocrine Carcinoma Report Years Considered

    Figure 13. Global Neuroendocrine Carcinoma Market Size (US$ Million), Year-over-Year: 2018-2029

    Figure 14. Global Neuroendocrine Carcinoma Market Size, (US$ Million), 2018 VS 2022 VS 2029

    Figure 15. Global Neuroendocrine Carcinoma Market Share by Region: 2022 VS 2029

    Figure 16. Global Neuroendocrine Carcinoma Market Share by Players in 2022

    Figure 17. Global Top Neuroendocrine Carcinoma Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuroendocrine Carcinoma as of 2022)

    Figure 18. The Top 10 and 5 Players Market Share by Neuroendocrine Carcinoma Revenue in 2022

    Figure 19. North America Neuroendocrine Carcinoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 20. North America Neuroendocrine Carcinoma Market Share by Country (2018-2029)

    Figure 21. United States Neuroendocrine Carcinoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 22. Canada Neuroendocrine Carcinoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 23. Europe Neuroendocrine Carcinoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 24. Europe Neuroendocrine Carcinoma Market Share by Country (2018-2029)

    Figure 25. Germany Neuroendocrine Carcinoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 26. France Neuroendocrine Carcinoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 27. U.K. Neuroendocrine Carcinoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 28. Italy Neuroendocrine Carcinoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 29. Russia Neuroendocrine Carcinoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 30. Nordic Countries Neuroendocrine Carcinoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 31. Asia-Pacific Neuroendocrine Carcinoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 32. Asia-Pacific Neuroendocrine Carcinoma Market Share by Region (2018-2029)

    Figure 33. China Neuroendocrine Carcinoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 34. Japan Neuroendocrine Carcinoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 35. South Korea Neuroendocrine Carcinoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 36. Southeast Asia Neuroendocrine Carcinoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 37. India Neuroendocrine Carcinoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 38. Australia Neuroendocrine Carcinoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 39. Latin America Neuroendocrine Carcinoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 40. Latin America Neuroendocrine Carcinoma Market Share by Country (2018-2029)

    Figure 41. Mexico Neuroendocrine Carcinoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 42. Brazil Neuroendocrine Carcinoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 43. Middle East & Africa Neuroendocrine Carcinoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 44. Middle East & Africa Neuroendocrine Carcinoma Market Share by Country (2018-2029)

    Figure 45. Turkey Neuroendocrine Carcinoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 46. Saudi Arabia Neuroendocrine Carcinoma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 47. Pfizer Revenue Growth Rate in Neuroendocrine Carcinoma Business (2018-2023)

    Figure 48. Novartis Revenue Growth Rate in Neuroendocrine Carcinoma Business (2018-2023)

    Figure 49. Chiasma Revenue Growth Rate in Neuroendocrine Carcinoma Business (2018-2023)

    Figure 50. Ipsen Revenue Growth Rate in Neuroendocrine Carcinoma Business (2018-2023)

    Figure 51. Abbvie Revenue Growth Rate in Neuroendocrine Carcinoma Business (2018-2023)

    Figure 52. Valeant Revenue Growth Rate in Neuroendocrine Carcinoma Business (2018-2023)

    Figure 53. Jubilant Revenue Growth Rate in Neuroendocrine Carcinoma Business (2018-2023)

    Figure 54. Teva Revenue Growth Rate in Neuroendocrine Carcinoma Business (2018-2023)

    Figure 55. F.Hoffmann-La Roche Revenue Growth Rate in Neuroendocrine Carcinoma Business (2018-2023)

    Figure 56. Advanced Accelerator Revenue Growth Rate in Neuroendocrine Carcinoma Business (2018-2023)

    Figure 57. Mateon Revenue Growth Rate in Neuroendocrine Carcinoma Business (2018-2023)

    Figure 58. Lexicon Revenue Growth Rate in Neuroendocrine Carcinoma Business (2018-2023)

    Figure 59. Bottom-up and Top-down Approaches for This Report

    Figure 60. Data Triangulation

    Figure 61. Key Executives Interviewed